会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 72. 发明授权
    • Azo pigments derived from 2-hydroxynaphthalene-3-carboxylic acid or its
salts having improved color
    • 衍生自2-羟基萘-3-羧酸的偶氮颜料或其盐具有改进的颜色
    • US4530724A
    • 1985-07-23
    • US413797
    • 1982-09-01
    • Ryuzo UenoHiroaki TsuchiyaShigeru Itoh
    • Ryuzo UenoHiroaki TsuchiyaShigeru Itoh
    • C09B29/15C09B67/20C09B67/22C09B29/01
    • C09B67/0046C09B29/103
    • The color of azo pigments derived from 2-hydroxynaphthalene-3-carboxylic acid or its salts are improved by the coupling reaction of a diazonium compound of an aromatic aminosulfonic acid with a coupling component which is a mixture of (1) 2-hydroxynaphthalene-3-carboxylic acid or its salt, (2) .beta.-naphthol or its salt, and (3) a phenolic by-product having a molecular weight of about 300 and containing about 1 equivalent of phenolic hydroxy groups. The phenolic by-product can be obtained by evaporating .beta.-naphthol from a tarry substance formed as a by-product during the reaction of an alkali .beta.-naphtholate with carbon dioxide, extracting the residue with an alkali and precipitating the soluble matter with an acid. The color or tone of the azo pigment is stabilized by the use of the coupling component. The azo pigments range from those having dark color and a greater degree of transparency which are suitable for use in printing inks to those having increased brightness which are suitable for use in paints.
    • 通过芳香族氨基磺酸的重氮化合物与作为(1)2-羟基萘-3的混合物的偶合成分的偶联反应,可以改善由2-羟基萘-3-甲酸或其盐衍生的偶氮颜料的颜色 - 羧酸或其盐,(2)β-萘酚或其盐,和(3)分子量约为300并含有约1当量酚羟基的酚类副产物。 酚类副产物可以通过在碱性β-萘酚与二氧化碳的反应期间从作为副产物形成的焦油状物质中蒸发β-萘酚获得,用碱萃取残余物并用酸沉淀可溶物质 。 通过使用偶联组分使偶氮颜料的颜色或色调稳定。 偶氮颜料的范围从具有深色和较高透明度的那些,其适用于将油墨用于具有适合用于涂料中的亮度增加的那些。
    • 74. 发明授权
    • Sorbic acid-containing powder or granules
    • 含有山梨酸的粉末或颗粒
    • US4308281A
    • 1981-12-29
    • US9348
    • 1979-02-05
    • Ryuzo UenoToshio MatsudaShigeo Inamine
    • Ryuzo UenoToshio MatsudaShigeo Inamine
    • A23L3/34A23C19/082A23C19/10A23K1/16A23K3/00A23L1/00A23L3/3508C07C51/00C07C51/50C07C57/10C07C67/00A61K31/19
    • A23C19/082A23C19/10A23K30/00A23L3/3508A23P10/47
    • Sorbic acid-containing powder or granules free from scatterability and rapidly soluble in water consisting of 5-90% by weight of finely divided sorbic acid with particle diameter of 50.mu. or less, 10-95% by weight of an easily water-soluble substance which is a solid at normal temperature and 0-2% by weight of hydrophilic surface active agent, characterized by having particle diameter of 300.mu. or more. The above sorbic acid-containing powder or granules can be obtained by drying after making powder or granules having particle diameter of 300.mu. or more from a mixture consisting of finely divided sorbic acid with particle diameter of 50.mu. or less, an easily water-soluble substance which is solid at normal temperature, water and/or an aqueous organic solvent and optionally, a hydrophilic surface active agent, or by making powder or granules having particle diameter of 300.mu. or more from the dry mixture after drying said mixture.
    • 含有山梨酸的粉末或颗粒无分散性,并且易溶于水,其含量为5-90重量%,粒径为50微米或更小的细分山梨酸,10-95重量%易溶于水的物质 其在常温下为固体,0-2重量%的亲水性表面活性剂,其特征在于粒径为300μm以上。 上述含山梨酸粉末或颗粒剂可以由粒径为50微米或更小的细分山梨酸组成的混合物制成粒径为300微米以上的粉末或颗粒之后进行干燥,易溶于水 在常温下为固体的物质,水和/或水性有机溶剂和任选的亲水性表面活性剂,或在干燥所述混合物之后,从干燥混合物制备粒径为300μm以上的粉末或颗粒。
    • 76. 发明授权
    • Ocular hypotensive agents
    • 眼低血压药
    • US06420422B1
    • 2002-07-16
    • US08476583
    • 1995-06-07
    • Ryuzo UenoRyuji UenoTomio Oda
    • Ryuzo UenoRyuji UenoTomio Oda
    • A61K31455
    • A61K31/557C07C405/00
    • The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of 20-substituted-PGs or 20-substituted 15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like. The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.
    • 本发明涉及一种眼部降血压药物组合物和治疗青光眼的组合物,其含有作为眼部降压药有效的20-取代的PG或20-取代的15-酮基-PG的量; 这些化合物没有或没有副作用,例如暂时性高眼压反应,结膜充血或虹膜,泪囊虫,莱马,闭眼等。本发明涉及含有13,14-二氢-15- 酮前列腺素,其不显示PG通常显示的暂时性高眼压反应。